Is moderate red wine consumption safe in inactive inflammatory bowel disease?

Digestion

Volumn 84, Issue 3, 2011, Pages 238-244

  Swanson, Garth R ^a   Tieu, Vanessa ^a   Shaikh, Maliha ^a   Forsyth, Chris ^a   Keshavarzian, Ali ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alcohol consumption; Crohn's disease; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; SUGAR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RECURRENT DISEASE; RED WINE; SYMPTOM; ULCERATIVE COLITIS; URINALYSIS;

ADULT; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; HUMANS; INTESTINES; LACTULOSE; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MANNITOL; MIDDLE AGED; PERMEABILITY; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SUCROSE; WINE; YOUNG ADULT;

EID: 80052094159     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000329403     Document Type: Article

References (36)

1. Molodecky NA, Kaplan GG: Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (NY) 2010; 6: 339-346.
2. Cottone M, Rosselli M, Orlando A, et al: Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643-648. (Pubitemid 24064330)
3. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP: Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-1099. (Pubitemid 32246663)
4. Green JT, Rhodes J, Ragunath K, et al: Clinical status of ulcerative colitis in patients who smoke. Am J Gastroenterol 1998; 93: 1463-1467. (Pubitemid 29075183)
5. Aldhous MC, Drummond HE, Anderson N, et al: Smoking habit and load influence age at diagnosis and disease extent in ulcerative colitis. Am J Gastroenterol 2007; 102: 589-597. (Pubitemid 46328159)
6. Patel M, Keshavarzian A, Kottapalli V, Badie B, Winship D, Fields JZ: Human neutrophil functions are inhibited in vitro by clinically relevant ethanol concentrations. Alcohol Clin Exp Res 1996; 20: 275-283. (Pubitemid 26117898)
7. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13: 267-276.
8. Bjarnason I, Peters TJ, Wise RJ: The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984; 1: 179-182. (Pubitemid 14221988)
9. Tang Y, Forsyth CB, Banan A, Fields JZ, Keshavarzian A: Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. J Pharmacol Exp Ther 2009; 329: 952-958.
10. Mutlu E, Keshavarzian A, Engen P, Forsyth CB, Sikaroodi M, Gillevet P: Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009; 33: 1836-1846.
11. Jowett SL, Seal CJ, Pearce MS, et al: Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004; 53: 1479-1484. (Pubitemid 39265269)
12. Hey H, Schmedes A, Nielsen AA, Winding P, Gronbaek H: Effects of five different alcoholic drinks on patients with Crohn's disease. Scand J Gastroenterol 2007; 42: 968-972. (Pubitemid 47037121)
13. Swanson GR, Sedghi S, Farhadi A, Keshavarzian A: Pattern of alcohol consumption and its effect on gastrointestinal symptoms in inflammatory bowel disease. Alcohol 2010; 44: 223-228.
14. Wyatt J, Oberhuber G, Pongratz S, et al: Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 1997; 92: 1891-1896. (Pubitemid 27440914)
15. Arnott ID, Kingstone K, Ghosh S: Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000; 35: 1163-1169.
16. Wild GE, Waschke KA, Bitton A, Thomson AB: The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 2003; 18: 309-317. (Pubitemid 37046710)
17. Gisbert JP, Bermejo F, Perez-Calle JL, et al: Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190-1198.
18. Sandborn WJ, Feagan BG, Hanauer SB, et al: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-530. (Pubitemid 34117002)
19. Farhadi A, Keshavarzian A, Fields JZ, Sheikh M, Banan A: Resolution of common dietary sugars from probe sugars for test of intestinal permeability using capillary column gas chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 836: 63-68.
20. Farhadi A, Keshavarzian A, Holmes EW, Fields J, Zhang L, Banan A: Gas chromatographic method for detection of urinary sucralose: application to the assessment of intestinal permeability. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 145-154. (Pubitemid 36009351)
21. Anderson AD, Poon P, Greenway GM, Mac-Fie J: A simple method for the analysis of urinary sucralose for use in tests of intestinal permeability. Ann Clin Biochem 2005; 42: 224-226. (Pubitemid 40694964)
22. Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-431. (Pubitemid 43268284)
23. Sakamoto N, Kono S, Wakai K, et al: Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005; 11: 154-163. (Pubitemid 40711220)
24. Mawdsley JE, Macey MG, Feakins RM, Langmead L, Rampton DS: The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology 2006; 131: 410-419. (Pubitemid 44142453)
25. Keefer L, Stepanski EJ, Ranjbaran Z, Benson LM, Keshavarzian A: An initial report of sleep disturbance in inactive inflammatory bowel disease. J Clin Sleep Med 2006; 2: 409-416. (Pubitemid 44763800)
26. Reid MC, Fiellin DA, O'Connor PG: Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 1999; 159: 1681-1689. (Pubitemid 29379129)
27. Adams PF, Schoenborn CA: Health behaviors of adults: United States, 2002-04. Vital Health Stat 10 2006; 230: 1-140.
28. Szabo G, Mandrekar P: A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 2009; 33: 220-232.
29. Bode C, Bode JC: Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res 2005; 29: 166S-171S. (Pubitemid 43194346)
30. Lakatos PL, Kiss LS, Palatka K, et al: Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011; 17: 767-777.
31. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G: Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009; 15: 100-113.
32. Costa F, Mumolo MG, Ceccarelli L, et al: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368. (Pubitemid 40299092)
33. Shah VO, Ferguson JE, Hunsaker LA, Deck LM, Vander Jagt DL: Natural products inhibit LPS-induced activation of pro-inflammatory cytokines in peripheral blood mononuclear cells. Nat Prod Res 2010; 24: 1177-1188.
34. Yusuf N, Nasti TH, Meleth S, Elmets CA: Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinog 2009; 48: 713-723.
35. Montalto M, Gallo A, Ferrulli A, et al: Fecal calprotectin concentrations in alcoholic patients: a longitudinal study. Eur J Gastroenterol Hepatol 2011; 23: 76-80.
36. O'Keefe JH, Bybee KA, Lavie CJ: Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol 2007; 50: 1009-1014. (Pubitemid 47348233)